文献速递膀胱癌与上尿路尿路上皮癌

组织学变异型尿路上皮癌患者接受三联膀胱保留治疗的临床结局

Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
PubMed 文献 · Eur Urol · 2016-12-28

这项单中心回顾性研究纳入1993年至2013年接受三联膀胱保留治疗(TMT)的303例患者,其中66例(22%)为变异型尿路上皮癌(VUC)。VUC与纯尿路上皮癌(PUC)在诱导TMT后的完全缓解率、总生存、疾病特异性生存及挽救性膀胱切除率上均无显著差异。作者结论认为,VUC的存在不应将患者排除在TMT之外。

要点

  • 303例接受TMT的患者中66例(22%)为VUC,其中50例(76%)伴鳞状和/或腺样分化。
  • 诱导TMT后完全缓解率PUC 83% vs VUC 82%(p=0.9)。
  • 多因素分析中VUC与DSS(HR 1.3,95%CI 0.8-2.2,p=0.3)及OS(HR 1.2,95%CI 0.8-1.7,p=0.4)无显著关联。

核心结论

  • VUC对TMT有应答,与PUC相比在完全缓解率、OS、DSS或挽救性膀胱切除率上无显著差异。
  • 作者认为,VUC的存在不应将患者排除在TMT之外。

研究设计与样本

  • 单中心回顾性研究,纳入1993年至2013年接受TMT治疗的患者。
  • 共303例接受TMT,其中66例(22%)为VUC;VUC中50例(76%)伴鳞状和/或腺样分化,16例(24%)为其他形式。

主要发现

  • 诱导TMT后完全缓解率PUC 83% vs VUC 82%(p=0.9)。
  • 5年和10年疾病特异性生存(DSS)PUC 75%和67% vs VUC 64%和64%。
  • 5年和10年总生存(OS)PUC 61%和42% vs VUC 52%和42%。
  • 多因素分析中VUC与DSS无显著关联(HR 1.3,95%CI 0.8-2.2,p=0.3),与OS亦无显著关联(HR 1.2,95%CI 0.8-1.7,p=0.4)。
  • 挽救性膀胱切除率相似(log-rank p=0.3)。

关键数值与推荐

  • 完全缓解率:PUC 83% vs VUC 82%(p=0.9)。
  • 5年/10年DSS:PUC 75%/67% vs VUC 64%/64%。
  • 5年/10年OS:PUC 61%/42% vs VUC 52%/42%。
  • DSS的多因素HR 1.3(95%CI 0.8-2.2,p=0.3);OS的多因素HR 1.2(95%CI 0.8-1.7,p=0.4)。
  • 挽救性膀胱切除率log-rank p=0.3。

临床怎么用

  • 作者认为,VUC的存在不应将患者排除在TMT之外。

局限性

  • 回顾性设计。
  • 限于尿路上皮癌的变异型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trimodality bladder-sparing therapy (TMT) is an acceptable treatment for selected patients with muscle-invasive urothelial cancer. Outcomes of TMT in histologic variants remains largely unknown. OBJECTIVE: To compare outcomes of pure urothelial carcinoma (PUC) to variant urothelial carcinoma (VUC) after TMT. DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of patients treated with TMT at a single cancer center from 1993 until 2013. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier survival probabilities, and univariate and multivariable Cox regression analysis. RESULTS AND LIMITATIONS: Of 303 patients treated with TMT, 66 (22%) had VUC. Fifty (76%) had VUC with squamous and/or glandular differentiation and 16 (24%) had other forms. Complete response rate after induction TMT was 83% in PUC and 82% in VUC (p=0.9). The 5-yr and 10-yr disease-specific survival (DSS) was 75% and 67% in PUC versus 64% and 64% in VUC. The 5-yr and 10-yr overall survival (OS) was 61% and 42% in PUC versus 52% and 42% in VUC. On multivariable analysis VUC was not associated with DSS (hazard ratio: 1.3, 95% confidence interval: 0.8-2.2, p=0.3) or OS (hazard ratio: 1.2, 95% confidence interval: 0.8-1.7, p=0.4). Salvage cystectomy rates were similar (log-rank p=0.3). Limitations include retrospective design and restriction to variants of urothelial cancer. CONCLUSIONS: VUC responded to TMT, and there was no significant difference in complete response, OS, DSS, or salvage cystectomy rates compared with PUC. The presence of VUC should not exclude patients from TMT. PATIENT SUMMARY: The response of histologic variants of bladder cancer to bladder-sparing chemoradiation is largely unknown. We compared the outcomes of histologic variants of urothelial cancer to pure urothelial cancer in a large series of patients from a single institution. We found that variant histology does not significantly influence outcomes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Krasnow RE, Drumm M, Roberts HJ, et al. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol. 2016. PMID: 28040351. doi:10.1016/j.eururo.2016.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。